Phosphodiesterase 5 inhibitors and adrenal incidentalomas

Med Hypotheses. 2019 Sep:130:109288. doi: 10.1016/j.mehy.2019.109288. Epub 2019 Jun 24.

Authors

Ioannis Ilias¹, Lina Zabuliene²

Affiliations

¹ Endocrine Unit, Elena Venizelou Hospital, Athens GR-11521, Greece. Electronic address: iiliasmd@yahoo.com.
² Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Ciurlionio 21, Vilnius LT-03101, Lithuania. Electronic address: lina.zabuliene@mf.vu.lt.

PMID: 31262442
DOI: 10.1016/j.mehy.2019.109288

No abstract available

Publication types

Letter

MeSH terms

Adrenal Gland Neoplasms / chemically induced*
Adrenal Gland Neoplasms / epidemiology
Adrenal Glands / drug effects
Humans
Male
Phosphodiesterase 5 Inhibitors / adverse effects*
Prevalence
Protein Isoforms
Retrospective Studies

Substances

Phosphodiesterase 5 Inhibitors
Protein Isoforms

Supplementary concepts

Adrenal incidentaloma